anti-trem2 monoclonal antibody eos006215
anti-trem2 monoclonal antibody eos006215: sourced relationships with 1 company · 1 clinical trial tracked.
anti-trem2 monoclonal antibody eos006215 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could anti-trem2 monoclonal antibody eos006215 → ITOS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| iTeos Therapeutics, Inc. (ITOS) Antagonize TREM2 to inhibit tumor-resident TREM2-expressing … | Phase 1 |
Clinical Trial Registry Records (1)
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
Primary endpoint: Incidence of dose-limiting toxicities (DLTs), adverse events (AEs)/serious adverse events (SAEs) [Safety and Tolerability]
Frequently asked questions
Which companies have sourced relationships with anti-trem2 monoclonal antibody eos006215?
anti-trem2 monoclonal antibody eos006215 has dated SEC/FDA relationship records for iTeos Therapeutics, Inc..
How many clinical trials involve anti-trem2 monoclonal antibody eos006215?
BioSniper tracks 1 clinical trial involving anti-trem2 monoclonal antibody eos006215.